BUYSELL, INTLOOP

As of March 30, UBS <7685> maintains a BUY rating,东海东京<9556> maintains an OUTPERFORM rating in the INTL LOOP. The above ratings are based on our company's confirmation as of the specified date.

Fisco JapanMar 30 04:27 ET

Shareholding ratio report for INTLOOP (70.85% → 70.85%) by Masahiro Hayashi, et al.

Submitter: Hirofumi Hayashi Submission Date and Time: March 30, 2026, 13:43 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 10) Reporting Obligation Trigger Date: March 23, 2026 Reason for Submission of Amendment Report: Execution of significant contracts such as security agreements related to the relevant share certificates Issuer: INTLOOP Co., Ltd. [Summary Table] Ownership Percentage (%): 70.8

Jiji PressMar 30 00:46 ET

The market remained sluggish, weighed down by declines in U.S. stocks and rising crude oil prices.

[Emerging Market Stock Strategy] The emerging market is expected to remain subdued today. In the U.S. stock market on the 18th, the Dow Jones Industrial Average fell significantly by 768.11 points (-1.63%) to 46,225.15, marking its first decline in three days. This downturn was driven by a further rise in crude oil prices after Iran reported attacks on oil-related facilities, as well as a stronger-than-expected acceleration in the Producer Price Index (PPI), which dampened expectations for interest rate cuts, weighing on stock prices. Additionally, Federal Reserve Chair Jerome Powell...

Fisco JapanMar 18 19:20 ET

Ribomic, Chordia, and others

SB C&S, which handles the manufacturing, distribution, and sales of IT-related products under the 149A classification, has entered into a capital and business alliance. Chordia has initiated dosing for the first patient in an expanded cohort under the 190A classification. Free Cloud acquired shares of Logikura, which plans, develops, and operates the logistics platform service 'Logikura,' thereby making it a subsidiary under the 4478 classification. Finally, Ribomic has progressed to Phase III clinical trials in Japan for its cartilage hypoplasia treatment (umedaptanib pegol) under the 4591 classification.

Fisco JapanMar 18 18:30 ET

INTLOOP to Acquire Financial IT Specialist CSS to Deepen DX Push in Banking Sector

TipRanksMar 18 03:00 ET

INTLOOP Projects Strong FY2026 Growth on Expanded Consolidation and Stable Capital Base

TipRanksMar 12 22:52 ET